INTRODUCTION: This research aimed to demonstrate the correlation of circulating endothelial cells (CECs) count and serum cytokine levels with side effects and prognosis in rectal cancer patients receiving adjuvant chemoradiation. METHODS: Eleven patients received proctectomy, chemoradiotherapy and follow-up for 4 years. Fifty-five blood samples were taken before radiation and during the course. The quantities of CECs were estimated by flow cytometry, and serological factors were measured by ELISA. RESULTS: The CEC level in patients without tumor recurrence was significantly lower than in patients with tumor recurrence (p < 0.01). The IL-6 and TGF-β1 levels exhibited a similar profile (p < 0.01). For morbidity, the mean CEC level in patients with grade 3 diarrhea was significantly greater than patients with grades 1 (p < 0.001) and 2 diarrhea (p < 0.005). CONCLUSIONS: Levels of CECs, serum IL-6, TGF-β1 and TNF-α during post-operative chemoradiation in rectal cancer patients might be candidate biomarkers for prognosis and morbidity (NCT00325871).
INTRODUCTION: This research aimed to demonstrate the correlation of circulating endothelial cells (CECs) count and serum cytokine levels with side effects and prognosis in rectal cancerpatients receiving adjuvant chemoradiation. METHODS: Eleven patients received proctectomy, chemoradiotherapy and follow-up for 4 years. Fifty-five blood samples were taken before radiation and during the course. The quantities of CECs were estimated by flow cytometry, and serological factors were measured by ELISA. RESULTS: The CEC level in patients without tumor recurrence was significantly lower than in patients with tumor recurrence (p < 0.01). The IL-6 and TGF-β1 levels exhibited a similar profile (p < 0.01). For morbidity, the mean CEC level in patients with grade 3 diarrhea was significantly greater than patients with grades 1 (p < 0.001) and 2 diarrhea (p < 0.005). CONCLUSIONS: Levels of CECs, serum IL-6, TGF-β1 and TNF-α during post-operative chemoradiation in rectal cancerpatients might be candidate biomarkers for prognosis and morbidity (NCT00325871).
Authors: Patricia E Burger; Sandra Coetzee; Wallace L McKeehan; Mikio Kan; Perry Cook; Yong Fan; Toshio Suda; Robert P Hebbel; Nicolas Novitzky; William A Muller; E Lynette Wilson Journal: Blood Date: 2002-11-15 Impact factor: 22.113
Authors: E Friedman; L I Gold; D Klimstra; Z S Zeng; S Winawer; A Cohen Journal: Cancer Epidemiol Biomarkers Prev Date: 1995 Jul-Aug Impact factor: 4.254
Authors: Al B Benson; Jaffer A Ajani; Robert B Catalano; Constance Engelking; Steven M Kornblau; James A Martenson; Richard McCallum; Edith P Mitchell; Thomas M O'Dorisio; Everett E Vokes; Scott Wadler Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: Stephen Sonis; Linda Elting; Dorothy Keefe; Hoang Nguyen; Steven Grunberg; Pamela Randolph-Jackson; Michael Brennan Journal: Support Care Cancer Date: 2014-08-16 Impact factor: 3.603
Authors: B Rovati; S Mariucci; S Delfanti; D Grasso; C Tinelli; C Torre; M De Amici; P Pedrazzoli Journal: Cell Oncol (Dordr) Date: 2016-01-14 Impact factor: 6.730
Authors: Nuh N Rahbari; Sebastian Schölch; Ulrich Bork; Christoph Kahlert; Martin Schneider; Mohammad Rahbari; Markus W Büchler; Jürgen Weitz; Christoph Reissfelder Journal: Oncotarget Date: 2017-06-06